Plain-English translation of NCT06980532 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether two medications called glumetinib and fruquintinib, given together, can help people with advanced colorectal cancer that has spread and stopped responding to previous treatments. The trial focuses specifically on patients whose cancer has a certain genetic change (called MET amplification or overexpression) that might make it respond to this medication combination. Researchers want to understand how well this treatment works and what side effects people experience.
Many people with advanced colorectal cancer run out of treatment options after trying two or more standard therapies. This trial exists because early research suggests that this medication combination may help patients whose cancer has specific genetic changes, offering a new hope for those with limited options.
You likely qualify if…
You likely don't qualify if…
You would receive the two medications (glumetinib and fruquintinib) as part of this study, which is designed to test both how well the treatment works and its safety. You'll have regular visits for blood tests, imaging scans to measure your cancer, and check-ups to monitor how you're doing. The trial involves both early-stage testing (Phase 1/2), so your doctors will carefully watch for side effects and adjust your dose if needed to find the safest and most effective approach.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
China